330 related articles for article (PubMed ID: 15034075)
1. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses.
Lu J; Higashimoto Y; Appella E; Celis E
J Immunol; 2004 Apr; 172(7):4575-82. PubMed ID: 15034075
[TBL] [Abstract][Full Text] [Related]
2. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
3. TAP-independent presentation of CTL epitopes by Trojan antigens.
Lu J; Wettstein PJ; Higashimoto Y; Appella E; Celis E
J Immunol; 2001 Jun; 166(12):7063-71. PubMed ID: 11390450
[TBL] [Abstract][Full Text] [Related]
4. Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction.
Miconnet I; Coste I; Beermann F; Haeuw JF; Cerottini JC; Bonnefoy JY; Romero P; Renno T
J Immunol; 2001 Apr; 166(7):4612-9. PubMed ID: 11254719
[TBL] [Abstract][Full Text] [Related]
5. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine.
Leitch J; Fraser K; Lane C; Putzu K; Adema GJ; Zhang QJ; Jefferies WA; Bramson JL; Wan Y
J Immunol; 2004 May; 172(9):5200-5. PubMed ID: 15100257
[TBL] [Abstract][Full Text] [Related]
6. In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes.
Nelson D; Bundell C; Robinson B
J Immunol; 2000 Dec; 165(11):6123-32. PubMed ID: 11086045
[TBL] [Abstract][Full Text] [Related]
7. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses.
Vabulas RM; Pircher H; Lipford GB; Häcker H; Wagner H
J Immunol; 2000 Mar; 164(5):2372-8. PubMed ID: 10679072
[TBL] [Abstract][Full Text] [Related]
8. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.
Krishnan L; Sad S; Patel GB; Sprott GD
J Immunol; 2000 Nov; 165(9):5177-85. PubMed ID: 11046050
[TBL] [Abstract][Full Text] [Related]
9. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
Rice J; Buchan S; Stevenson FK
J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
[TBL] [Abstract][Full Text] [Related]
10. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; Onoé K
J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735
[TBL] [Abstract][Full Text] [Related]
11. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity.
Bijker MS; van den Eeden SJ; Franken KL; Melief CJ; Offringa R; van der Burg SH
J Immunol; 2007 Oct; 179(8):5033-40. PubMed ID: 17911588
[TBL] [Abstract][Full Text] [Related]
12. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
[TBL] [Abstract][Full Text] [Related]
13. A CD8+ T cell heptaepitope minigene vaccine induces protective immunity against Chlamydia pneumoniae.
Pinchuk I; Starcher BC; Livingston B; Tvninnereim A; Wu S; Appella E; Sidney J; Sette A; Wizel B
J Immunol; 2005 May; 174(9):5729-39. PubMed ID: 15843575
[TBL] [Abstract][Full Text] [Related]
14. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
[TBL] [Abstract][Full Text] [Related]
15. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines.
Rice J; Elliott T; Buchan S; Stevenson FK
J Immunol; 2001 Aug; 167(3):1558-65. PubMed ID: 11466377
[TBL] [Abstract][Full Text] [Related]
16. Generation of autoreactive CTL by tumour vaccines containing foreign T helper epitopes.
Steinaa L; Rasmussen PB; Rygaard J; Mouritsen S; Gautam A
Scand J Immunol; 2007 Mar; 65(3):240-8. PubMed ID: 17309778
[TBL] [Abstract][Full Text] [Related]
17. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
18. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
[TBL] [Abstract][Full Text] [Related]
19. Influence of strong CD4 epitope on long-term virus-specific cytotoxic T cell responses induced in vivo with peptides.
Sauzet JP; Gras-Masse H; Guillet JG; Gomard E
Int Immunol; 1996 Apr; 8(4):457-65. PubMed ID: 8671632
[TBL] [Abstract][Full Text] [Related]
20. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL.
Nelson DJ; Mukherjee S; Bundell C; Fisher S; van Hagen D; Robinson B
J Immunol; 2001 May; 166(9):5557-66. PubMed ID: 11313395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
